Raphael Pharmaceutical Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
RAPHStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Interim Statements of Cash Flows
| Three months ended March 31, | ||||
|---|---|---|---|---|
| 2026 · 2025 | ||||
| Cash flows from operating activities | ||||
| Net loss | $(229) | $(429) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation | (* | ) | (* | ) |
| Share-based compensation | - | 197 | ||
| Interest accrued | 3 | - | ||
| Changes in: | ||||
| Other current assets | 6 | (35) | ||
| Account payables and related parties | 176 | 58 | ||
| Net cash used in operating activities | (44) | (209) | ||
| Cash flows from investing activities | ||||
| Purchase of fixed assets | - | - | ||
| Net cash used in investing activities | - | - | ||
| Cash flows from financing activities | ||||
| Issuance of common stock and warrants** | - | 240 | ||
| Net cash provided by financing activities | - | 240 | ||
| Change in cash and cash equivalents | (44) | 31 | ||
| Cash and cash equivalents at the beginning of the period | 45 | 19 | ||
| Cash and cash equivalents at the end of the period | $1 | $50 | ||
| (*) | less than $1 thousand |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.